The REVLIRIT CLL5 AGMT Study – a Phase I/II Trial Combining Fludarabine/Rituximab with Escalating Doses of Lenalidomide Followed by Rituximab/Lenalidomide in Untreated Chronic Lymphocytic Leukemia (CLL): Results of a Planned Interim Analysis

Egle, A, Steurer, M, Melchardt, T, Stoll, M, Greil, R